Uveal melanoma: Recent advances in immunotherapy

Area of Science:

• Ophthalmology
• Oncology
• Immunology

Background:

• Uveal melanoma (UM) is the most common primary intraocular cancer in adults.
• While primary UM is often locally controlled, up to 50% of patients develop fatal liver metastases.
• Current treatments for metastatic UM, including chemotherapy and immune checkpoint inhibitors, show limited efficacy.

Purpose of the Study:

• To review novel immunotherapeutic strategies for uveal melanoma.
• To highlight recent insights into UM's unique immune microenvironment.
• To discuss the development of tailored treatments for UM.

Main Methods:

• Review of clinical and preclinical studies on UM immunotherapy.
• Analysis of UM's distinct genetic mutations (GNAQ/GNA11) compared to cutaneous melanoma (BRAF/NRAS).
• Examination of the complex interaction between UM and the immune system.

Main Results:

• Immunotherapy, including immune checkpoint inhibitors, has shown limited success in ocular UM.
• UM's unique genetic profile influences its response to treatment.
• Novel approaches like cancer vaccines and adoptive cell transfer are under investigation.

Conclusions:

• Metastatic uveal melanoma remains a challenge with poor prognosis and limited treatment options.
• Understanding UM's distinct biology is crucial for developing effective immunotherapies.
• Further research into tailored immunotherapeutic strategies is essential for improving patient outcomes.